Effects of Dapagliflozin on Body Weight in Japanese Patients with Type 2 Diabetes Mellitus. SUMS-ADDIT-2
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000020239
- Lead Sponsor
- Shiga University of Medical Science
- Brief Summary
The change in BM was significantly larger in the Dapa than in the Con group, with a difference in the mean change of-1.72 kg (95 %CI: -2.85, -0.59; P = 0.004) between the groups. IHTG content was significantly reduced in the Dapa than in the Con (P = 0.033). Changes in AAs showed small differences between the groups, but only serine concentrations were significantly reduced in the Dapa.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 52
Not provided
1) History of receiving a SGLT-2 inhibitor 2) Receiving insulin or GLP-1 agonist 3) With severe ketosis, diabetic coma, or precoma 4) Contraindication to the use of dapagliflozin (history of hypersensitivity to dapagliflozin, or pregnant, etc.) 5) History of hospitalization for infection, trauma, or surgery within 6 months 6) History or under treatment of brain infarction, transient ischemic attack 7) With an episode of angina pectoris or myocardial infarction within 6 months 8) Receiving loop diuretics 9) With orthostatic hypotension 10) Considered inadequate by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in body weight from 0 to 24 weeks
- Secondary Outcome Measures
Name Time Method